Coversyl: Effective Blood Pressure Control for Cardiovascular Health
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.61 | $48.19 (0%) | 🛒 Add to cart |
| 60 | $1.41 | $96.39 $84.34 (13%) | 🛒 Add to cart |
| 90 | $1.20 | $144.58 $108.44 (25%) | 🛒 Add to cart |
| 120 | $1.15 | $192.78 $138.56 (28%) | 🛒 Add to cart |
| 180 | $1.10 | $289.17 $198.80 (31%) | 🛒 Add to cart |
| 270 | $0.90 | $433.75 $243.99 (44%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $578.34 $289.17 (50%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.01 | $40.16 (0%) | 🛒 Add to cart |
| 30 | $1.71 | $60.24 $51.21 (15%) | 🛒 Add to cart |
| 60 | $1.51 | $120.49 $90.36 (25%) | 🛒 Add to cart |
| 90 | $1.34 | $180.73 $120.49 (33%) | 🛒 Add to cart |
| 120 | $1.20 | $240.97 $144.58 (40%) | 🛒 Add to cart |
| 180 | $1.15 | $361.46 $207.84 (42%) | 🛒 Add to cart |
| 270 | $1.10 | $542.19 $298.20 (45%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $722.92 $361.46 (50%) | 🛒 Add to cart |
| Product dosage: 8mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $3.01 | $60.24 (0%) | 🛒 Add to cart |
| 30 | $2.81 | $90.36 $84.34 (7%) | 🛒 Add to cart |
| 60 | $2.61 | $180.73 $156.63 (13%) | 🛒 Add to cart |
| 90 | $2.41 | $271.09 $216.88 (20%) | 🛒 Add to cart |
| 120 | $2.21 | $361.46 $265.07 (27%) | 🛒 Add to cart |
| 180 | $2.01 | $542.19 $361.46 (33%) | 🛒 Add to cart |
| 270 | $1.71 | $813.28 $460.86 (43%) | 🛒 Add to cart |
| 360 | $1.51
Best per pill | $1084.38 $542.19 (50%) | 🛒 Add to cart |
Coversyl (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor medication clinically proven to manage hypertension and improve cardiovascular outcomes. As a first-line treatment option, it works by relaxing blood vessels, allowing blood to flow more smoothly and reducing the heart’s workload. This comprehensive guide provides healthcare professionals and informed patients with detailed information regarding its proper use, mechanism, and safety profile.
Features
- Active ingredient: Perindopril arginine or Perindopril erbumine
- Medication class: Angiotensin-converting enzyme (ACE) inhibitor
- Available formulations: 2.5 mg, 5 mg, and 10 mg tablets
- Administration route: Oral
- Standard packaging: Blister packs of 30 tablets
- Prescription status: Requires medical prescription in most jurisdictions
Benefits
- Effectively lowers both systolic and diastolic blood pressure measurements
- Reduces the risk of major cardiovascular events in patients with stable coronary artery disease
- Demonstrates protective effects on endothelial function and vascular health
- May decrease proteinuria in diabetic patients with renal involvement
- Provides 24-hour blood pressure control with once-daily dosing in most patients
- Shows evidence of reducing left ventricular hypertrophy in hypertensive patients
Common use
Coversyl is primarily indicated for the treatment of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also approved for the management of stable coronary artery disease to reduce the risk of cardiovascular events in patients with a history of myocardial infarction or revascularization procedures. Additionally, it may be used in heart failure management as part of a comprehensive treatment regimen under specialist supervision.
Dosage and direction
The recommended initial dose for hypertension treatment is 4 mg once daily, which may be increased to 8 mg after one month if adequate blood pressure control is not achieved. For elderly patients or those with renal impairment, starting with 2 mg daily is advised. Tablets should be taken orally, preferably at the same time each day, with or without food. Dosage adjustments should be made gradually under medical supervision, with blood pressure monitoring conducted regularly to assess therapeutic response. For patients with congestive heart failure, treatment should be initiated under close medical supervision, typically starting with 2 mg daily.
Precautions
Patients should be monitored for the development of angioedema, particularly during the first month of treatment. Renal function and serum potassium levels should be assessed before initiation and periodically during therapy, especially in patients with pre-existing renal impairment or those taking potassium supplements. Blood pressure measurements should be taken regularly to ensure appropriate therapeutic response. Caution is advised in patients with aortic stenosis or hypertrophic cardiomyopathy. Patients should be informed about the potential for dizziness, especially during the initial treatment period or when rising quickly from a sitting or lying position.
Contraindications
Coversyl is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy. It should not be used in patients with hereditary or idiopathic angioedema. Additional contraindications include hypersensitivity to perindopril or any other ACE inhibitor, second and third trimester of pregnancy, and bilateral renal artery stenosis. Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment.
Possible side effect
Common adverse reactions may include cough (typically dry and persistent), dizziness, headache, fatigue, and asthenia. Less frequently reported effects include gastrointestinal disturbances, rash, taste disturbance, and hypotension. Serious but rare side effects may include angioedema, neutropenia/agranulocytosis, hepatic failure, and pancreatitis. Renal impairment may occur, particularly in volume-depleted patients or those with pre-existing renal disease. Patients should report any signs of infection, such as fever or sore throat, which could indicate neutropenia.
Drug interaction
Coversyl may interact with diuretics, potentially causing excessive blood pressure reduction. Concurrent use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to hyperkalemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect and increase the risk of renal impairment. Lithium levels may increase when co-administered with ACE inhibitors. Dual blockade of the renin-angiotensin system with ARBs, ACE inhibitors, or aliskiren increases the risk of hypotension, hyperkalemia, and renal impairment.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in dosing is important for maintaining stable blood pressure control, so patients should establish a routine to minimize missed doses.
Overdose
Symptoms of overdose may include severe hypotension, circulatory shock, electrolyte disturbances, and renal failure. Bradycardia may also occur. Management should focus on supportive measures, including volume expansion with intravenous normal saline to treat hypotension. Perindopril may be removed from the body by hemodialysis. Patients suspected of overdose should receive immediate medical attention with continuous monitoring of vital signs and electrolyte balance.
Storage
Coversyl tablets should be stored at room temperature (15-30°C or 59-86°F) in their original packaging to protect from light and moisture. The medication should be kept out of reach of children and pets. Tablets should not be used beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through pharmacy take-back programs rather than flushing or household trash disposal.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional who can consider individual patient circumstances. Dosage and administration may vary based on specific clinical situations. Patients should not alter their treatment regimen without consulting their prescribing physician.
Reviews
Clinical studies have demonstrated Coversyl’s efficacy in blood pressure management, with many patients achieving target blood pressure goals. The ASCOT-BPLA trial showed significant cardiovascular risk reduction with perindopril-based therapy. Many physicians appreciate its once-daily dosing and generally favorable side effect profile. Some patients report the persistent dry cough as a reason for discontinuation, while others tolerate the medication well long-term. Real-world evidence supports its position as a well-established option in hypertension management protocols.